Eliem Therapeutics Current Ratio 2021-2024 | CLYM
Eliem Therapeutics current ratio from 2021 to 2024. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
| Eliem Therapeutics Current Ratio Historical Data |
| Date |
Current Assets |
Current Liabilities |
Current Ratio |
| 2024-06-30 |
$0.23B |
$0.00B |
60.41 |
| 2024-03-31 |
$0.11B |
$0.00B |
37.03 |
| 2023-12-31 |
$0.11B |
$0.00B |
38.92 |
| 2023-09-30 |
$0.11B |
$0.00B |
38.76 |
| 2023-06-30 |
$0.11B |
$0.00B |
31.58 |
| 2023-03-31 |
$0.12B |
$0.01B |
24.45 |
| 2022-12-31 |
$0.13B |
$0.01B |
22.04 |
| 2022-09-30 |
$0.13B |
$0.01B |
21.21 |
| 2022-06-30 |
$0.13B |
$0.01B |
17.48 |
| 2022-03-31 |
$0.13B |
$0.01B |
19.33 |
| 2021-12-31 |
$0.15B |
$0.01B |
24.58 |
| 2021-09-30 |
$0.16B |
$0.01B |
28.38 |
| 2021-06-30 |
$0.11B |
$0.01B |
18.35 |
| 2021-03-31 |
$0.00B |
|
0.00 |
| 2020-12-31 |
$0.00B |
|
0.00 |
| 2020-09-30 |
$0.00B |
|
0.00 |
| 2020-06-30 |
$0.00B |
|
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-DRUGS |
$0.342B |
$0.000B |
|
Eliem Therapeutics Inc. is a clinical-stage biotechnology company. It focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Eliem Therapeutics Inc. is based in SEATTLE, United Kingdom.
|
